1.Curative effect of Budesonide combined with Salbutamol in treatment of children with bronchial asthma
Shaofeng YANG ; Xuri LUO ; Jitao LIN
Chinese Journal of Primary Medicine and Pharmacy 2010;17(12):1615-1616
Objective To investigate the effect of Budesonide combined with Salbutamol in treatment of chil-dren with bronchial asthma.Methods 100 cases of children with asthma were randomly divided into conventional therapy group(Group A)50 cases and combined treatment group(Group B)50 cases;Conventional therapy was given to group B and Group A Was givend the conventional therapy puls Budesonide combined with salbutamol treatment,2 times a day.The course of treatment was 10d;The effect of clinical symptom score、clinical recovery and adverse reac-tions in two groups were observed.Results The total efficiency of 47 cases(94.O%) in group A were significantly higher than the B group 36 cases(72.0%)(P<0.05);The index of breathing diffculties、coushing、wheezing、wheezing sustain and sleep satisfaction after treatment were significantly decreased compared with before treatment in two groups(all P<0.01);The time of recovery of breath shortness、cough、asthma、wheezing and therapy hys in group A were less than group B(all P<0.05).Condusion Atomizing inhalation treatment of Bedesonide combined with Sallbutamol was effective to treat children with bronchial asthma.
2.Discovery of a new nosiheptide-producing strain and its fermentation optimization for nosiheptide production
Qihang SUN ; Yuncong XU ; Lingrui WU ; Jiale RONG ; Yanwen WANG ; Yudan CAO ; Chen LUO ; Xuri WU
Journal of China Pharmaceutical University 2022;53(6):725-733
Nosiheptide is a typical thiopeptide antibiotic displaying potent activity toward various drug-resistant strains of Gram-positive pathogens.Although nosiheptide lacks in vivo activity, and good water-solubility with a series of uncontrollable analogues, which may limit its clinical application, glycosylated analogues may overcome problem of low activity and may improve its druggability.In search of novel glycosylated nosiheptide producers, we applied a genome mining strategy that identified Actinoalloteichus sp.AHMU CJ021 that contains all genes required.However, despite the presence of a predicted glycosyltransferase, glycosylated derivatives of nosiheptide were not detected, after following one strain many compounds (OSMAC) strategy and heterologous expression of a regulatory protein NocP.Nevertheless, nosiheptide produced by this strain was remarkably pure, and further experiments were conducted to improve its production by optimization of the culture medium.Under optimal conditions, 58.73 mg/L nosiheptide was produced, representing an almost 6-fold improvement compared to the original fermentation medium.Therefore, we consider Actinoalloteichus sp.AHMU CJ021 a suitable potential candidate for industrial production of nosiheptide, which provides the basis for solving the problem of nosiheptide structural analogues.